CureDuchenne was founded 25 years ago, and during that time we have witnessed and participated in the approval of multiple FDA-approved therapies, dozens of clinical trials, and an expanding pipeline of investigational treatments. But there is still no cure for Duchenne, and important challenges remain to be solved.
For families living with Duchenne, every scientific breakthrough brings hope, and every clinical trial represents another possibility. Real progress requires the combined efforts of researchers, clinicians, biotechnology companies, families, regulators, venture capital investorsand advocacy organizations working together to effectively treat complex diseases like Duchenne and Becker muscular dystrophy.
That’s how medical progress happens.
Why Developing New Duchenne Treatments Takes Time
Developing new treatments for complex diseases is one of the most challenging endeavors in medicine. Every potential therapy requires years of painstaking research, followed by preclinical and IND-enabling studies and regulatory review before it can be be tested in a clinical trial in patients.
One thing is certain in drug development: every new approach to treatment will encounter challenges along the way, many of which are impossible to anticipate.
This is not unique to Duchenne; it’s the reality of drug development. Every well-designed study, whether it succeeds or falls short, adds to our understanding of the disease and helps inform how to design and test better treatments.
These lessons have been applied to Duchenne and Becker research, where an improved understanding of the disease natural history has aided biomarker development, improved endpoints, and patient reported outcomes as important components of clinical trial design.
Why Duchenne Requires Multiple Therapeutic Approaches
The goal of Duchenne research is to restore the missing dystrophin protein as completely as possible in every person living with Duchenne.
That is the aim of approaches like exon skipping and gene therapy, which have transformed the treatment landscape over this past decade and have provided meaningful treatment options for some patients living with Duchenne.
But these therapies have limitations. Eligibility may depend on an individual’s specific mutation, age, stage of disease, or other factors. And even for those eligible, currently approved treatments do not fully restore normal levels of dystrophin expression throughout the body, limiting their overall benefit.
For this reason, researchers continue to pursue next-generation “dystrophin-restoring” therapies designed to improve on today’s treatments. They are also exploring new technologies and approaches that could overcome current limitations. For example, non-viral delivery approaches could potentially deliver full-length natural dystrophin and allow for redosing.
It’s believed that a combination of different therapeutic agents, working together and targeting distinct components of the disease, will be required to more fully address the challenge of treating Duchenne muscular dystrophy. This includes reducing chronic inflammation and subsequent fibrosis, as well as addressing muscle regeneration in older individuals living with Duchenne.
How CureDuchenne Helps Move Science Forward
By closely evaluating the Duchenne research landscape,CureDuchenne Ventures identifies the greatest scientific opportunities, unmet needs, and areas where new approaches could move the field forward.
Our Ventures team brings decades of drug development and investment experience evaluating science projects and emerging therapies to identify the most promising opportunities for people living with Duchenne and Becker muscular dystrophy.
Our goal is not to fund the most ideas. It is to identify and accelerate the best ones.
That allows us to invest in science that addresses critical unmet needs, whether that’s advancing next-generation exon-skipping therapies, overcoming current limitations of gene delivery and gene editing, supporting muscle regeneration, or developing new bespoke approaches for individuals with Duchenne that have limited treatment options.
But funding is only the beginning.
CureDuchenne works alongside researchers and biotechnology companies throughout the process, providing expertise in preclinical development, clinical strategy, trial design, regulatory planning, and patient engagement to help move promising therapies from discovery to patients.
That approach has guided CureDuchenne for more than two decades. Companies behind six of the eight FDA-approved Duchenne therapies received early support from CureDuchenne, demonstrating our ability to identify promising science early and help advance it toward patients.
Looking Ahead
Today, there are multiple FDA-approved therapies, more clinical trials than ever before, and an expanding pipeline of innovative science.
That progress is real. But families still need treatments that are more effective, more durable, and available to everyone living with Duchenne. Getting there will require continued scientific innovation and investment in the most promising ideas.
CureDuchenne is committed to helping move the best science forward by funding research and helping to accelerate the development of better treatments. Because every person living with Duchenne deserves the very best that science can deliver.
Related Resources
Learn more about Duchenne research and the therapies shaping the future:
- Duchenne Therapeutic Pipeline – Explore FDA-approved therapies and investigational treatments.
- Clinical Trials – Learn about ongoing clinical research and how new therapies are evaluated.
- CureDuchenne Ventures – See how early-stage investments help accelerate breakthrough science.
- Research News – Read the latest updates on CureDuchenne-funded research and scientific progress.
- Schedule a 1:1 with CureDuchenne experts for personalized support
The post Building a Stronger Therapeutic Pipeline for Duchenne appeared first on CureDuchenne.